SCHEMBL4925702

SCHEMBL4925702

Cc1ccc(-c2cc(=O)c3cc(Cl)cc(Cl)c3o2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 9/20 0.62
CSNK2B P67870 9/20 0.62
CSNK2A1 P68400 9/20 0.62
MAOB P27338 3/20 0.52
TNKS O95271 1/20 0.52
PARP1 P09874 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
CYP1A1 P04798 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP1B1 Q16678 2/20 0.52
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
GABRP O00591 2/20 0.46
GABRD O14764 2/20 0.46
GABRA1 P14867 2/20 0.46
GABRB1 P18505 2/20 0.46
GABRG2 P18507 2/20 0.46
GABRB3 P28472 2/20 0.46
GABRA5 P31644 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649989 0.89 CSNK2A2 (0.62) CSNK2A2CSNK2BCSNK2A1TNKSCYP1A1
SCHEMBL15231415 0.85 CSNK2A2 (0.65) CSNK2A2CSNK2BCSNK2A1MAOBTNKS
SCHEMBL4649950 0.85 TNKS (0.61) CSNK2A2CSNK2BCSNK2A1MAOBTNKS
SCHEMBL24046751 0.80 CSNK2A2 (0.67) CSNK2A2CSNK2BCSNK2A1CYP1A1CYP1A2
SCHEMBL11802722 0.78 ESR1 (0.55) CSNK2A2CSNK2BCSNK2A1MAOB
SCHEMBL24046919 0.77 CSNK2A2 (0.50) CSNK2A2CSNK2BCSNK2A1TNKSCYP1A1
SCHEMBL21959063 0.76 CSNK2A2 (0.48) CSNK2A2CSNK2BCSNK2A1MAOBCYP1A1
SCHEMBL21886746 0.74 CSNK2A2 (0.56) CSNK2A2CSNK2BCSNK2A1MAOBTNKS
SCHEMBL16342832 0.72 ABCG2 (0.66) CSNK2A2CSNK2BCSNK2A1MAOB
SCHEMBL4650552 0.72 CSNK2A2 (0.74) CSNK2A2CSNK2BCSNK2A1MAOBTNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287374-A1 BREAST CANCER-RESISTANT PROTEIN INHIBITOR KABUSHIKI KAISHA YAKULT HONSHA (JP) 2008-11-20 US disclosed
US-20060135445-A1 Breast cancer-resistant protein inhibitor KABUSHIKI KAISHA YAKULT HONSHA (JP) 2006-06-22 US disclosed
EP-1591112-A1 BREAST CANCER-RESISTANT PROTEIN INHIBITOR Kabushiki Kaisha Yakult Honsha (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135445-A1 Breast cancer-resistant protein inhibitor ABCC1, BCR, BRCA1 CSNK2A2 2298/4885CSNK2B 2245/4885CSNK2A1 2290/4885
US-20080287374-A1 BREAST CANCER-RESISTANT PROTEIN INHIBITOR ABCC1, BCR, BRCA1 CSNK2A2 2298/4885CSNK2B 2245/4885CSNK2A1 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.